U.S. President Donald Trump signed an executive order on April 18 that will expand and fund research into the use of psychedelic substances to treat mental health issues. For the first time in decades, the federal government is not just tolerating or indirectly funding research into psychedelic substances. This time Trump has decided to actually promote it at the federal level, focusing his efforts above all on ibogaine. But this is not the only substance that has received the green light. The c
U.S. President Donald Trump signed an executive order on April 18 that will expand and fund research into the use of psychedelic substances to treat mental health issues. For the first time in decades, the federal government is not just tolerating or indirectly funding research into psychedelic substances. This time Trump has decided to actually promote it at the federal level, focusing his efforts above all on ibogaine. But this is not the only substance that has received the green light. The clinical trials already underway with psilocybin and MDMA have been also been given a boost.
Login
New York Times World News
TheHill - Just In
El País in English
